Profile of immediate adverse reactions to chemotherapy infusion in outpatients at a University Hospital in the state of Rio de Janeiro
Autor(a) principal: | |
---|---|
Data de Publicação: | 2021 |
Outros Autores: | , |
Tipo de documento: | Artigo |
Idioma: | por |
Título da fonte: | Research, Society and Development |
Texto Completo: | https://rsdjournal.org/index.php/rsd/article/view/23009 |
Resumo: | Most antineoplastic agents can cause infusion reactions, the incidence and profile of which vary according to the characteristics of each drug, which may or may not be immune-mediated. In order to describe the profile of immediate adverse reactions to chemotherapy infusion in outpatients, we developed this exploratory, descriptive, cross-sectional and retrospective study, based on records of adverse reaction notifications carried out by the multidisciplinary team from March/2018 to March/2019, and the medical records of the participants. Adverse reactions immediate to chemotherapy infusion were ranked for severity according to the Common Terminology Criteria for Adverse Events and for causality using Naranjo's algorithm. Of a total of 6,832 intravenous chemotherapy facilities performed during the study period, 30 immediate adverse reactions were recorded, involving 28 patients (83% women), mainly with Paclitaxel (44%) and Carboplatin (20%). According to Naranjo, 60% of infusion reactions were classified as probable. The mean time for onset of reactions was 40 minutes, being the fastest with Docetaxel (5 minutes) and the longest with Paclitaxel (180 minutes). The severity of reactions ranged from mild (64%) to moderate (30%). The most compromised organic segments were respiratory (27%) and cardiovascular (26%); and 83% of the symptoms presented were predicted in the databases. With this study, it was possible to identify the main immediate reactions to the infusion in the study group, as well as the chemotherapeutic agents involved with them, contributing to the safe management of patients and effective control of reactions by the multidisciplinary team. |
id |
UNIFEI_13b57a038a457a0dac6b8d3e75b4674c |
---|---|
oai_identifier_str |
oai:ojs.pkp.sfu.ca:article/23009 |
network_acronym_str |
UNIFEI |
network_name_str |
Research, Society and Development |
repository_id_str |
|
spelling |
Profile of immediate adverse reactions to chemotherapy infusion in outpatients at a University Hospital in the state of Rio de JaneiroPerfil de reacciones adversas inmediatas a la infusión de quimioterapia en pacientes ambulatorios de un Hospital Universitario de Río de JaneiroPerfil das reações adversas imediatas à infusão de quimioterapia em pacientes ambulatoriais em um Hospital Universitário fluminense QuimioterapiaEventos adversosFarmacovigilânciaSegurança do paciente.QuimioterapiaEventos adversosFarmacovigilanciaSeguridad del paciente.ChemotherapyAdverse eventsPharmacovigilancePatient safety.Most antineoplastic agents can cause infusion reactions, the incidence and profile of which vary according to the characteristics of each drug, which may or may not be immune-mediated. In order to describe the profile of immediate adverse reactions to chemotherapy infusion in outpatients, we developed this exploratory, descriptive, cross-sectional and retrospective study, based on records of adverse reaction notifications carried out by the multidisciplinary team from March/2018 to March/2019, and the medical records of the participants. Adverse reactions immediate to chemotherapy infusion were ranked for severity according to the Common Terminology Criteria for Adverse Events and for causality using Naranjo's algorithm. Of a total of 6,832 intravenous chemotherapy facilities performed during the study period, 30 immediate adverse reactions were recorded, involving 28 patients (83% women), mainly with Paclitaxel (44%) and Carboplatin (20%). According to Naranjo, 60% of infusion reactions were classified as probable. The mean time for onset of reactions was 40 minutes, being the fastest with Docetaxel (5 minutes) and the longest with Paclitaxel (180 minutes). The severity of reactions ranged from mild (64%) to moderate (30%). The most compromised organic segments were respiratory (27%) and cardiovascular (26%); and 83% of the symptoms presented were predicted in the databases. With this study, it was possible to identify the main immediate reactions to the infusion in the study group, as well as the chemotherapeutic agents involved with them, contributing to the safe management of patients and effective control of reactions by the multidisciplinary team.La mayoría de los agentes antineoplásicos pueden producir reacciones a la infusión, cuya incidencia y perfil varían según las características de cada fármaco, que pueden ser inmunomediadas o no. Con el fin de describir el perfil de reacciones adversas inmediatas a la infusión de quimioterapia en pacientes ambulatorios, se desarrolló este estudio exploratorio, descriptivo, transversal y retrospectivo, basado en registros de notificaciones de reacciones adversas realizadas por el equipo multidisciplinario de marzo / 2018 a marzo / 2019, y la historia clínica de los participantes. Las reacciones adversas inmediatas a la infusión de quimioterapia se clasificaron por gravedad de acuerdo con los Criterios de terminología común para eventos adversos y por causalidad utilizando el algoritmo de Naranjo. De un total de 6.832 instalaciones de quimioterapia intravenosa realizadas durante el período de estudio, se registraron 30 reacciones adversas inmediatas, involucrando a 28 pacientes (83% mujeres), principalmente con Paclitaxel (44%) y Carboplatino (20%). Según Naranjo, el 60% de las reacciones a la infusión se clasificaron como probables. El tiempo medio de aparición de reacciones fue de 40 minutos, siendo el más rápido con Docetaxel (5 minutos) y el más largo con Paclitaxel (180 minutos). La gravedad de las reacciones varió de leve (64%) a moderada (30%). Los segmentos orgánicos más comprometidos fueron el respiratorio (27%) y el cardiovascular (26%); y el 83% de los síntomas presentados se predijeron en las bases de datos. Con este estudio fue posible identificar las principales reacciones inmediatas a la infusión en el grupo de estudio, así como los agentes quimioterapéuticos involucrados en las mismas, contribuyendo al manejo seguro de los pacientes y al control efectivo de las reacciones por parte del equipo multidisciplinar.A maioria dos agentes antineoplásicos pode ocasionar reações infusionais, das quais a incidência e o perfil variam conforme as características de cada medicamento, podendo ou não ser imunomediadas. Com o objetivo descrever o perfil das reações adversas imediatas à infusão de quimioterapia em pacientes ambulatoriais, desenvolvemos este estudo exploratório, descritivo, transversal e retrospectivo, a partir registros das notificações das reações adversas realizados pela equipe multiprofissional de março/2018 a março/2019, e dos prontuários dos participantes. As reações adversas imediatas à infusão de quimioterapia foram classificadas quanto à gravidade, de acordo com a Common Terminology Criteria for Adverse Events, e quanto à causalidade usando algoritmo de Naranjo. De um total de 6.832 instalações endovenosas de quimioterapia realizadas no período de estudo, foram registradas 30 reações adversas imediatas, envolvendo 28 pacientes (83% mulheres), principalmente com Paclitaxel (44%) e Carboplatina (20%). Conforme Naranjo, 60% das reações infusionais foram classificadas como prováveis. O tempo médio para manifestação das reações foi de 40 minutos, sendo a mais rápida com Docetaxel (5 minutos), e a mais demorada com Paclitaxel (180 minutos). A gravidade das reações variou entre leve (64%) e moderada (30%). Os segmentos orgânicos mais comprometidos foram respiratório (27%) e cardiovascular (26%); e 83% dos sintomas apresentados estavam previstos nas bases de dados. Com este estudo, foi possível identificar as principais reações imediatas à infusão no grupo em estudo, bem como os quimioterápicos envolvidos com as mesmas, contribuindo para o manejo seguro dos pacientes e no controle eficaz das reações pela equipe multidisciplinar.Research, Society and Development2021-11-29info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://rsdjournal.org/index.php/rsd/article/view/2300910.33448/rsd-v10i15.23009Research, Society and Development; Vol. 10 No. 15; e416101523009Research, Society and Development; Vol. 10 Núm. 15; e416101523009Research, Society and Development; v. 10 n. 15; e4161015230092525-3409reponame:Research, Society and Developmentinstname:Universidade Federal de Itajubá (UNIFEI)instacron:UNIFEIporhttps://rsdjournal.org/index.php/rsd/article/view/23009/20448Copyright (c) 2021 Maihara da Silva Borges; Marcela Miranda Salles; Ranieri Carvalho Camuzihttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessBorges, Maihara da SilvaSalles, Marcela MirandaCamuzi, Ranieri Carvalho2021-12-06T10:13:53Zoai:ojs.pkp.sfu.ca:article/23009Revistahttps://rsdjournal.org/index.php/rsd/indexPUBhttps://rsdjournal.org/index.php/rsd/oairsd.articles@gmail.com2525-34092525-3409opendoar:2024-01-17T09:42:00.399208Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)false |
dc.title.none.fl_str_mv |
Profile of immediate adverse reactions to chemotherapy infusion in outpatients at a University Hospital in the state of Rio de Janeiro Perfil de reacciones adversas inmediatas a la infusión de quimioterapia en pacientes ambulatorios de un Hospital Universitario de Río de Janeiro Perfil das reações adversas imediatas à infusão de quimioterapia em pacientes ambulatoriais em um Hospital Universitário fluminense |
title |
Profile of immediate adverse reactions to chemotherapy infusion in outpatients at a University Hospital in the state of Rio de Janeiro |
spellingShingle |
Profile of immediate adverse reactions to chemotherapy infusion in outpatients at a University Hospital in the state of Rio de Janeiro Borges, Maihara da Silva Quimioterapia Eventos adversos Farmacovigilância Segurança do paciente. Quimioterapia Eventos adversos Farmacovigilancia Seguridad del paciente. Chemotherapy Adverse events Pharmacovigilance Patient safety. |
title_short |
Profile of immediate adverse reactions to chemotherapy infusion in outpatients at a University Hospital in the state of Rio de Janeiro |
title_full |
Profile of immediate adverse reactions to chemotherapy infusion in outpatients at a University Hospital in the state of Rio de Janeiro |
title_fullStr |
Profile of immediate adverse reactions to chemotherapy infusion in outpatients at a University Hospital in the state of Rio de Janeiro |
title_full_unstemmed |
Profile of immediate adverse reactions to chemotherapy infusion in outpatients at a University Hospital in the state of Rio de Janeiro |
title_sort |
Profile of immediate adverse reactions to chemotherapy infusion in outpatients at a University Hospital in the state of Rio de Janeiro |
author |
Borges, Maihara da Silva |
author_facet |
Borges, Maihara da Silva Salles, Marcela Miranda Camuzi, Ranieri Carvalho |
author_role |
author |
author2 |
Salles, Marcela Miranda Camuzi, Ranieri Carvalho |
author2_role |
author author |
dc.contributor.author.fl_str_mv |
Borges, Maihara da Silva Salles, Marcela Miranda Camuzi, Ranieri Carvalho |
dc.subject.por.fl_str_mv |
Quimioterapia Eventos adversos Farmacovigilância Segurança do paciente. Quimioterapia Eventos adversos Farmacovigilancia Seguridad del paciente. Chemotherapy Adverse events Pharmacovigilance Patient safety. |
topic |
Quimioterapia Eventos adversos Farmacovigilância Segurança do paciente. Quimioterapia Eventos adversos Farmacovigilancia Seguridad del paciente. Chemotherapy Adverse events Pharmacovigilance Patient safety. |
description |
Most antineoplastic agents can cause infusion reactions, the incidence and profile of which vary according to the characteristics of each drug, which may or may not be immune-mediated. In order to describe the profile of immediate adverse reactions to chemotherapy infusion in outpatients, we developed this exploratory, descriptive, cross-sectional and retrospective study, based on records of adverse reaction notifications carried out by the multidisciplinary team from March/2018 to March/2019, and the medical records of the participants. Adverse reactions immediate to chemotherapy infusion were ranked for severity according to the Common Terminology Criteria for Adverse Events and for causality using Naranjo's algorithm. Of a total of 6,832 intravenous chemotherapy facilities performed during the study period, 30 immediate adverse reactions were recorded, involving 28 patients (83% women), mainly with Paclitaxel (44%) and Carboplatin (20%). According to Naranjo, 60% of infusion reactions were classified as probable. The mean time for onset of reactions was 40 minutes, being the fastest with Docetaxel (5 minutes) and the longest with Paclitaxel (180 minutes). The severity of reactions ranged from mild (64%) to moderate (30%). The most compromised organic segments were respiratory (27%) and cardiovascular (26%); and 83% of the symptoms presented were predicted in the databases. With this study, it was possible to identify the main immediate reactions to the infusion in the study group, as well as the chemotherapeutic agents involved with them, contributing to the safe management of patients and effective control of reactions by the multidisciplinary team. |
publishDate |
2021 |
dc.date.none.fl_str_mv |
2021-11-29 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://rsdjournal.org/index.php/rsd/article/view/23009 10.33448/rsd-v10i15.23009 |
url |
https://rsdjournal.org/index.php/rsd/article/view/23009 |
identifier_str_mv |
10.33448/rsd-v10i15.23009 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.none.fl_str_mv |
https://rsdjournal.org/index.php/rsd/article/view/23009/20448 |
dc.rights.driver.fl_str_mv |
Copyright (c) 2021 Maihara da Silva Borges; Marcela Miranda Salles; Ranieri Carvalho Camuzi https://creativecommons.org/licenses/by/4.0 info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
Copyright (c) 2021 Maihara da Silva Borges; Marcela Miranda Salles; Ranieri Carvalho Camuzi https://creativecommons.org/licenses/by/4.0 |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Research, Society and Development |
publisher.none.fl_str_mv |
Research, Society and Development |
dc.source.none.fl_str_mv |
Research, Society and Development; Vol. 10 No. 15; e416101523009 Research, Society and Development; Vol. 10 Núm. 15; e416101523009 Research, Society and Development; v. 10 n. 15; e416101523009 2525-3409 reponame:Research, Society and Development instname:Universidade Federal de Itajubá (UNIFEI) instacron:UNIFEI |
instname_str |
Universidade Federal de Itajubá (UNIFEI) |
instacron_str |
UNIFEI |
institution |
UNIFEI |
reponame_str |
Research, Society and Development |
collection |
Research, Society and Development |
repository.name.fl_str_mv |
Research, Society and Development - Universidade Federal de Itajubá (UNIFEI) |
repository.mail.fl_str_mv |
rsd.articles@gmail.com |
_version_ |
1797052790981263360 |